Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, detailed in a Current Report on Form 8-K filed with the SEC, revises the terms of the company's equity investments in Evofem. The third equity investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. Additionally, the fourth equity investment date has been extended from September 30, 2024, to October 31, 2024, with the investment amount increased from $1 million to $1.5 million. This follows a series of agreements and amendments starting from December 11, 2023, when Aditxt initially entered into a merger agreement with Evofem. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The...Show More

Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, detailed in a Current Report on Form 8-K filed with the SEC, revises the terms of the company's equity investments in Evofem. The third equity investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. Additionally, the fourth equity investment date has been extended from September 30, 2024, to October 31, 2024, with the investment amount increased from $1 million to $1.5 million. This follows a series of agreements and amendments starting from December 11, 2023, when Aditxt initially entered into a merger agreement with Evofem. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes forward-looking statements and a cautionary note indicating that the merger is subject to stockholder approval and other closing conditions. The company has also indicated that it will file a Proxy Statement / Registration Statement with the SEC, which will include a proxy statement/prospectus for the stockholders of Aditxt.